Podcast Episodes
Back to Search
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Season 7 Episode 369
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCen…
5 months, 2 weeks ago
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
Season 7 Episode 368
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bi…
5 months, 3 weeks ago
Ep. 367 - FDA, obesity targets and the rise of DACs
Season 7 Episode 367
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioC…
6 months ago
Ep. 366 - Europe's need for speed: Bio€quity takeaways
Season 7 Episode 366
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s ana…
6 months, 1 week ago
Ep. 365 - Thin ice for Makary, redosing AAVs
Season 7 Episode 365
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner sh…
6 months, 1 week ago
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
Season 7 Episode 364
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therape…
6 months, 2 weeks ago
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Season 7 Episode 653
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on ne…
6 months, 3 weeks ago
Ep. 362 - AACR: Data and de-risking
Season 7 Episode 362
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting…
6 months, 4 weeks ago
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
Season 7 Episode 361
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded …
7 months ago
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
Season 7 Episode 360
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Aus…
7 months, 1 week ago